Home » News » UK Pharmaceutical Companies Among the Most Affected

UK Pharmaceutical Companies Among the Most Affected

Since the UK left the EU, the pharmaceutical industry has had to adapt to many new regulations and processes. Understanding these could be crucial to remaining competitive and could even help you get ahead of EU and UK competitors.

Here are some of the most important provisions affecting pharmaceutical companies since the trade deal:

  • Rules of origin- Rules of Origin determine the ‘economic nationality’ of a good and could qualify you for lower or no customs duty. In order to qualify for lower or no tariffs, businesses need to sufficiently prove where their product originated from. These are particularly complicated when moving through multiple countries.
  • New MHRA policy- As as a result of the Brexit Deal, the MHRA became a standalone organization with its unique sets of regulations and processes, distinct from the EU. They have a brand new set of rules and regulations applying to UK firms.
  • Market licensing- Some of the most important regulations revolve around market authorization and licensing. Whether you are a new applicant or are in the process of applying, we can help.

Give us a call and we’ll take the headache away!